ezetimibe has been researched along with Diabetic Angiopathies in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Broncel, M; Gorzelak-Pabiś, P; Niedzielski, M; Woźniak, E | 1 |
| Grant, PJ | 1 |
| Bujas-Bobanovic, M; Ganda, OP; Koren, A; Leiter, LA; Letierce, A; Mandel, J; Plutzky, J; Sanganalmath, SK | 1 |
| Brath, H; Kästenbauer, T; Toplak, H; Wascher, TC | 1 |
| Chen, CY; Chen, JW; Chen, JY; Huang, PH; Lin, SJ; Shih, CC | 1 |
| Collins, PD; Sattar, N | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O | 1 |
| Michishita, I; Mizuguchi, I; Nozue, T; Sasaki, M; Tsunoda, T; Yamada, M | 1 |
| Cottrell, DA; Falko, JM; Marshall, BJ | 1 |
| Patel, J | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Böhm, F; Pernow, J; Rydén, L; Settergren, M | 1 |
5 review(s) available for ezetimibe and Diabetic Angiopathies
| Article | Year |
|---|---|
New possible pharmacological targets for statins and ezetimibe.
Topics: Animals; Atherosclerosis; Diabetic Angiopathies; Dyslipidemias; Endothelial Cells; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Signal Transduction | 2020 |
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Diabetic Angiopathies; Ezetimibe; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipid Metabolism; Meta-Analysis as Topic; Niacin; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size | 2003 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
3 trial(s) available for ezetimibe and Diabetic Angiopathies
| Article | Year |
|---|---|
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Brachial Artery; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Inflammation Mediators; Lipids; Male; Middle Aged; Plethysmography; Regional Blood Flow; Simvastatin; Vasodilation | 2008 |
7 other study(ies) available for ezetimibe and Diabetic Angiopathies
| Article | Year |
|---|---|
PCSK9 inhibitors- A new age in lipid management?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; PCSK9 Inhibitors; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk; Serine Proteinase Inhibitors | 2017 |
[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Topics: Ambulatory Care; Anticholesteremic Agents; Austria; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Utilization; Ezetimibe; Fibric Acids; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mass Screening; Risk Factors; Treatment Outcome; Triglycerides | 2012 |
Simvastatin pretreatment enhances ischemia-induced neovascularization and blood flow recovery in streptozotocin-treated mice.
Topics: Animals; Blood Flow Velocity; Collateral Circulation; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelial Progenitor Cells; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Phosphorylation; Recovery of Function; Regional Blood Flow; Simvastatin; Streptozocin; Time Factors; Vascular Endothelial Growth Factor A; Vasodilation | 2016 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides | 2010 |
Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Azetidines; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Female; Follow-Up Studies; Glucose Intolerance; Glycated Hemoglobin; Homeostasis; Humans; Japan; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Treatment Outcome; Weight Loss | 2013 |
[LDL cholesterol in cardiovascular risk patients should be as low as possible].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2007 |